PracticeUpdate Conference Series: IID 2018

*69% of patients achieved EASI-75 at 16 weeks and 65% achieved EASI-75 at 52 weeks. 1 See the evidence for continuous CONTROL * 1,2

Rapid # and sustained † improvement in: • Lesion extent and severity 1–4 • Pruritus intensity 1–4 • Quality-of-life measures 1,2 # Rapid – at 2 weeks. 1,2 † Sustained – out to 52 weeks. 1,2

52 week safety and tolerability profile with no monitoring for organ toxicities required 4 • The most common adverse reactions were injection site reactions, conjunctivitis, blepharitis, and oral herpes. 4

NOW TGA APPROVED 4

INDICATION DUPIXENT is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. Dupixent is not intended for episodic use. 4

PBS INFORMATION: This product is not listed on the PBS.

Before prescribing, please review Product Information available in the primary advertisement of this publication.

References: 1. Blauvelt A et al. Lancet. 2017; 389(10086):2287–2303. 2. Blauvelt A et al. Lancet. 2017; 389(10086). Supplementary Appendix. 3. Simpson EL. Dermatol Ther (Heidelb) 2017; 7(2):243–248. 4. Australian Approved Product Information for Dupixent.

Sanofi and Regeneron are collaborating in a global development program and commercialization for DUPIXENT.

© 2018 Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme – ALL RIGHTS RESERVED. Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme ABN 31 008 558 807. Talavera Corporate Centre. Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. www.sanofigenzyme.com.au. Date of preparation June 2018. GZANZ.DUP.18.02.0021a SAG0156/B

Made with FlippingBook - professional solution for displaying marketing and sales documents online